NASDAQ:ZLAB - Zai Lab Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $100.25
  • Forecasted Upside: -9.57 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$110.86
▲ +0.08 (0.07%)
1 month | 3 months | 12 months
Get New Zai Lab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZLAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZLAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$100.25
▼ -9.57% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is $100.25, with a high forecast of $111.00 and a low forecast of $84.00. The average price target represents a -9.57% upside from the last price of $110.86.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Zai Lab. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020JPMorgan Chase & Co.Boost Price Target$101.00 ➝ $111.00Low
i
11/3/2020JPMorgan Chase & Co.Boost Price TargetOverweight$65.00 ➝ $101.00Medium
i
9/10/2020SVB LeerinkBoost Price TargetOutperform$93.00 ➝ $95.00High
i
8/14/2020GuggenheimBoost Price TargetPositive ➝ Buy$105.00 ➝ $111.00Medium
i
Rating by Seamus Fernandez at Guggenheim
7/8/2020GuggenheimBoost Price TargetBuy$75.00 ➝ $105.00High
i
Rating by Seamus Fernandez at Guggenheim
7/7/2020SVB LeerinkBoost Price TargetOutperform$79.00 ➝ $93.00Low
i
4/27/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
i
4/15/2020GuggenheimInitiated CoverageBuy$75.00Low
i
12/30/2019CitigroupBoost Price TargetBuy$65.00 ➝ $84.00Low
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/4/2019CitigroupSet Price TargetBuy$65.00Low
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/4/2019SVB LeerinkSet Price TargetBuy$48.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
9/4/2019China Renaissance SecuritiesInitiated CoverageBuyHigh
i
7/15/2019SVB LeerinkSet Price TargetBuy$47.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
7/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$43.00Medium
i
7/5/2019MacquarieInitiated CoverageOutperform ➝ Outperform$36.54Low
i
6/11/2019SVB LeerinkSet Price TargetBuy$46.00Medium
i
Rating by Jonathan Chang at SVB Leerink LLC
1/29/2019Credit Suisse GroupInitiated CoverageOutperform$34.70High
i
11/21/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyLow
i
6/28/2018SVB LeerinkReiterated RatingOutperform$43.00Medium
i
Rating by J. Chang at SVB Leerink LLC
6/21/2018SVB LeerinkInitiated CoverageOutperform$43.00Medium
i
Rating by E. Darout at SVB Leerink LLC
3/23/2018SVB LeerinkReiterated RatingOutperformLow
i
Rating by E. Darout at SVB Leerink LLC
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00High
i
10/16/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$42.00N/A
i
Rating by S. Fernandez at SVB Leerink LLC
10/16/2017CitigroupInitiated CoverageBuyN/A
i
10/16/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$32.00N/A
i
(Data available from 12/1/2015 forward)
Zai Lab logo
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.
Read More

Today's Range

Now: $110.86
$109.70
$112.40

50 Day Range

MA: $93.86
$81.94
$108.14

52 Week Range

Now: $110.86
$38.06
$110.99

Volume

6,453 shs

Average Volume

431,984 shs

Market Capitalization

$6.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95